San Antonio, USA, July 10th 2014. Keraplast Technologies announced today that following evaluation at the specialist epidermolysis bullosa clinic at Great Ormond Street Hospital in London under the supervision of leading DEBRA Nurse Jackie Denyer, the keratin wound care gel keragelT® has been placed on the UK drug tariff list. This means clinicians and carers in the UK can now choose keragelT®, the latest tool for EB wound management, and have confidence that the care will be funded by the NHS.
In addition, H&R Healthcare has been appointed as UK distributor for the Keraplast wound care product range, including the keratin based products keragelT®, keragel®, keramatrix® and kerasorb®. This means that the only keratin based wound care products on the market are now available through the leading supplier of specialist wound care innovations in the UK.
Dr Rob Kelly, Interim Chief Executive Officers of Keraplast Technologies said “The unique approach to wound care that Replicine Functional Keratin provides is clearly solving unmet clinical needs in several disciplines, leading to growing interest in Europe. We are very pleased to be able to make a difference in the management epidermolysis bullosa and work closely with specialist clinics such as Great Ormond Street Hospital in London and EB Haus in Austria. Having keragelT® funded on the UK Drug Tariff will make a significant difference to families in the UK living with EB as they now have the latest advancement available to them. We are also seeing strong interest from groups working at the forefront of chronic wound care, such as the pressure ulcer group at Stoke Mandeville hospital who recently presented work on keragel® and keramatrix® at the 16th National Congress on Paraplegic Medicine in Italy.” He added “partnering with H&R Healthcare is perfect for us as they are clearly well recognised as being specialists at bringing wound care innovations into the UK healthcare system and we share the common goal of using innovation to improving patient outcomes.”
Mike Hoskins, Chief Executive Officer of H&R Healthcare said “our philosophy is
to offer innovative products that give the best overall value to the NHS, measured by patient outcomes and overall cost effectiveness. The Keraplast product range clearly provides this and we are excited about introducing this innovation to the UK.”